ARCHIMED has successfully completed the take-private acquisition of Instem, delisting the company from the London Stock Exchange (AIM). The transaction was driven by the need to liberate Instem from the short-term pressures of public reporting, allowing for more aggressive investment in long-term R&D. The strategic roadmap focuses on accelerating the adoption of "in silico" methods—using data and AI to model drug effects—which reduces the industry's reliance on animal testing and speeds up time-to-market. ARCHIMED intends to use Instem as a consolidation platform in the fragmented pre-clinical software market, leveraging its "MedTalents" network to source add-on acquisitions and drive international expansion.

INSTEM, which reported an EBITDA margin of LOGIN in 2022, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the 13.6x average currently observed in the TMT (Tech, Media, Telecom) sector.

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.